http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

While alcohol induces an increase of dopamine, ondansetron reduces the release of the neurotransmitter by blocking the 5-HT3 receptors. Several studies investigated the effectiveness of ondansetron by dividing alcoholic individuals into two subgroups based on their genotype for the promoter region of the SLC6A4 gene coding for the serotonin transporter (5-HTTLPR L/S polymorphism). The study showed that the patients with the LL genotype treated with ondansetron responded better in terms of alcohol amount and days of abstinence, compared to the other subgroups. Based on these results, researchers have further investigated genotype LL carriers, by analyzing the role of a functional polymorphism of the SLC6A4 gene (rs1042173 [T/G] SNP). The result was that individuals who carry both 5-HTTLPR LL polymorphism and rs1042173 TT polymorphism, treated with ondansetron at the dosage of 0.5 mg/die, present a more effective response to the drug. Unfortunately, the sample of this exploratory study was too small to be validated.

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_1574 DOID_1574

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/DRUGBANK:DB00904 DRUGBANK:DB00904

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RA59XSqRVP...#context context

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

https://pubmed.ncbi.nlm.nih.gov/29912214 pubmed.ncbi.nlm.nih.gov/29912214

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

0000-0002-7641-6446

2021-08-26T09:18:24.960Z

http://purl.org/np/RA59XSqRVP... RA59XSqRVP

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication

0000-0002-7641-6446

2021-08-26T09:18:24.960Z